Biomedicines and Bacterial Translocation in Spondyloarthritis

计划入组 90 人 · 首次发布于 2022 年 2 月 17 日

Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent

计划入组 42 人 · 首次发布于 2014 年 7 月 14 日

Safety and Efficacy Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent

计划入组 21 人 · 首次发布于 2014 年 10 月 3 日

SARS (Generate Biomedicines)

Ovarian cancer(Generate Biomedicines)

Anti-OX40L therapy(Generate Biomedicines)

Generate Biomedicines

Endeavor BioMedicines, Inc.

United States

Generate Biomedicines, Inc.

United States

Fortitude Biomedicines Launches with $13M Seed Funding to Advance Novel GLUE-DAC Platform for Cancer and Autoimmune Diseases

HYDRACs: Protein-Like Polymers Open New Frontier in Targeted Protein Degradation for Undruggable Cancer Targets

Avidity Biosciences Advances AOC 1020 for FSHD with Biomarker Cohort in FORTITUDE Trial